denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Adult, antibodies, Biological, therapy sequence, Diseases, neurotoxicity, Non-Biological, Combinations, Therapies, Adverse Events, chemotherapy, Biological Processes, T-Cell Lymphoma, Technology and Procedures, cytogenetics, epigenetics, Lymphoid Malignancies, Study Population, Clinically relevant, transplantation
Description:
Although there have been recent advances in the management of patients with aggressive lymphomas ranging from chimeric antigen receptor T-cell therapy to combination of antibody-drug conjugates with chemotherapy, significant challenges still exist in care delivery for this patient population. Such challenges include appropriate application of treatment advances to older patients with significant comorbidities, selection of effective treatments for patients with relapsed/refractory T-cell lymphomas, and timely integration of palliative care with disease-directed care. This educational session will explore the evidence for selecting treatments that balance efficacy with tolerability for less fit patients. It will also describe how to apply an understanding of subtypes of relapsed/refractory T-cell lymphoma to make effective treatment recommendations. Lastly, the session will discuss strategies to incorporate palliative care for patients with aggressive lymphomas.
Dr. Nancy Bartlett will outline the challenges of providing intensive treatment for patients with aggressive B-cell lymphomas who are over the age of 80 or have significant comorbidities. She will discuss evidence-based approaches of less-intensive yet effective treatments for this population. This talk will outline strategies by which to select treatment options that optimize efficacy while minimizing toxicity for less fit patients with aggressive B-cell lymphomas.
Dr. Lauren Pinter-Brown will outline recent advances in the treatment of aggressive T-cell lymphomas in the front-line setting. She will also discuss challenges regarding selecting patients who might benefit from consolidative autologous hematopoietic stem-cell transplant and treatment selection in the relapsed/refractory setting. Using a case-based format, Dr. Pinter-Brown will discuss how to apply an understanding of the subtypes of aggressive T-cell lymphomas to inform decision-making regarding consolidative transplant in the first-line setting and selection of treatment in the relapsed/refractory setting.
Dr. Oreofe Odejide will discuss the growing prognostic uncertainty that accompanies recent advances in the treatment of relapsed/refractory aggressive lymphomas and the challenge such uncertainty poses to integration of palliative care. This talk will discuss approaches for hematologic oncologists to provide primary palliative care for patients with relapsed/refractory disease and published tools to guide timely goals of care conversations. Dr. Odejide will also discuss approaches to integrate specialty palliative care for this patient population.
Dr. Nancy Bartlett will outline the challenges of providing intensive treatment for patients with aggressive B-cell lymphomas who are over the age of 80 or have significant comorbidities. She will discuss evidence-based approaches of less-intensive yet effective treatments for this population. This talk will outline strategies by which to select treatment options that optimize efficacy while minimizing toxicity for less fit patients with aggressive B-cell lymphomas.
Dr. Lauren Pinter-Brown will outline recent advances in the treatment of aggressive T-cell lymphomas in the front-line setting. She will also discuss challenges regarding selecting patients who might benefit from consolidative autologous hematopoietic stem-cell transplant and treatment selection in the relapsed/refractory setting. Using a case-based format, Dr. Pinter-Brown will discuss how to apply an understanding of the subtypes of aggressive T-cell lymphomas to inform decision-making regarding consolidative transplant in the first-line setting and selection of treatment in the relapsed/refractory setting.
Dr. Oreofe Odejide will discuss the growing prognostic uncertainty that accompanies recent advances in the treatment of relapsed/refractory aggressive lymphomas and the challenge such uncertainty poses to integration of palliative care. This talk will discuss approaches for hematologic oncologists to provide primary palliative care for patients with relapsed/refractory disease and published tools to guide timely goals of care conversations. Dr. Odejide will also discuss approaches to integrate specialty palliative care for this patient population.